BioCentury
ARTICLE | Clinical News

SGX94: Phase II started

December 16, 2013 8:00 AM UTC

Soligenix began a double-blind, placebo-controlled Phase II trial to evaluate SGX942 in patients undergoing chemoradiation therapy for head and neck cancer. SGX942 has Fast Track designation to treat OM as a result of radiation or chemotherapy in patients with head and neck cancer. The product also has Orphan Drug designation in the U.S. to treat acute radiation syndrome (ARS). ...